Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of MT200605 in acute ischemic stroke
CTR20253829Phase 2Active
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MT200605 in ischemic stroke, cerebral ischemia-reperfusion injury (CIRI), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
MT200605
03
Conditions
ischemic strokecerebral ischemia-reperfusion injury (CIRI)
Beyond the preview
Go deeper on CTR20253829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253829.